Nicolas M S Gálvez
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Gaspar A Pacheco
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Barbara M Schultz
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Felipe Melo-González
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Jorge A Soto
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Luisa F Duarte
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Liliana A Gonzalez
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Daniela S Rivera
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Mariana Ríos
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Roslye V Berrios
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Yaneisi Vázquez
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Daniela Moreno-Tapia
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Omar P Vallejos
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Catalina A Andrade
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Guillermo Hoppe-Elsholz
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Carolina Iturriaga
Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Marcela Urzua
Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
María S Navarrete
Departamento de Enfermedades Infecciosas del Adulto, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Álvaro Rojas
Departamento de Enfermedades Infecciosas del Adulto, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Rodrigo Fasce
Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Jorge Fernández
Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Judith Mora
Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Eugenio Ramirez
Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Aracelly Gaete-Argel
Laboratory of Molecular and Cellular Virology, University of Chile, Santiago, Chile
Competing interests
No competing interests declared.
Mónica Acevedo
Laboratory of Molecular and Cellular Virology, University of Chile, Santiago, Chile
Competing interests
No competing interests declared.
Fernando Valiente-Echeverria
Laboratory of Molecular and Cellular Virology, University of Chile, Santiago, Chile
Competing interests
No competing interests declared.
Ricardo Soto-Rifo
Laboratory of Molecular and Cellular Virology, University of Chile, Santiago, Chile
Competing interests
Ricardo Soto-Rifo, has received funding from ANID - ICM, ICN 2021_045. The author has no other competing interests to declare.
Daniela Weiskopf
Center for Infectious Disease and Vaccine Research, La Jolla Institute For Allergy & Immunology, La Jolla, United States
Competing interests
Daniela Weiskopf, has received funding support from the NIH under contract number 75N93019C00065. The Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. The author has no other competing interests to declare.
Alba Grifoni
Center for Infectious Disease and Vaccine Research, La Jolla Institute For Allergy & Immunology, La Jolla, United States
Competing interests
Alba Grifoni, Alba Grifoni has received funding support from the NIH under contract number 75N93021C00016. The Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. The author has no other competing interests to declare.
Alessandro Sette
Department of Medicine, University of California, San Diego, La Jolla, United States
Competing interests
Alessandro Sette, is a consultant for Gritstone Bio, Flow Pharma, Arcturus, Immunoscape, CellCarta, Moderna, AstraZeneca, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, Guggenheim, OxfordImmunotech, and Avalia. The author has received funding support from the NIH under contract 75N93021C00016. The Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. The author has no other competing interests to declare.
Gang Zeng
Sinovac Biotech, Beijing, China
Competing interests
Gang Zeng, is a SINOVAC employee and contributed to the conceptualization of the study (clinical protocol and eCRF design)..
Weining Meng
Sinovac Biotech, Beijing, China
Competing interests
Weining Meng, is a SINOVAC employee and contributed to the conceptualization of the study (clinical protocol and eCRF design)..
José V Gonzalez-Aramundiz
Departamento de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Marina Johnson
Department of Infection, University College London, London, United Kingdom
Competing interests
No competing interests declared.
David Goldblatt
Department of Infection, University College London, London, United Kingdom
Competing interests
No competing interests declared.
Pablo A González
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
Pablo A González, acts as the Executive Director of the clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.govNCT04651790) (funds to the institution), and receives research support from Millennium Institute on Immunology and Immunotherapy. The author received funding from Agencia Nacional de Investigación y Desarrollo, Fondo de Fomento al Desarrollo Científico y tecnológico. The author has no other competing interests to declare.
Katia Abarca
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
No competing interests declared.
Susan M Bueno
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
Susan M Bueno, acts as the Scientific Director of clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.govNCT04651790) (funds to the institution), and receives research support from Millennium Institute on Immunology and Immunotherapy. The author has received funding from Agencia Nacional de Invetsigación y Desarrollo, Fondo de Fomento al Desarrollo Científico y tecnológico ID20I10082. The author has no other competing interests to declare.
Alexis M Kalergis
Departamento de Genética Molecular y Microbiología, Pontificia Universidad Católica de Chile, Santiago, Chile
Competing interests
Alexis M Kalergis, acts as the General Director of clinical trials PedCoronaVac03CL clinical study (ClinicalTrials.gov NCT04992260) and CoronaVac03CL (ClinicalTrials.govNCT04651790). The author has received funding from Agencia Nacional de Investigación y Desarrollo (ANID) - Millennium Science Initiative Program - ICN09_016 / ICN 2021_045: Millennium Institute on Immunology and Immunotherapy (ICN09_016 / ICN 2021_045; former P09/016-F) and Agencia Nacional de Investigación y Desarrollo [FONDECYT grant numbers 1190830. The author has no other competing interests to declare.
Ministry of Health, Government of Chile (N/A)
The Confederation of Production and Commerce, Chile (N/A)
The Millenium Institute in Immunology and Immunotherapy (ICN09_016)
- Pablo A González
- Susan M Bueno
- Alexis M Kalergis
The Innovation fund for competitiveness FIC-R 2017 (30488811-0)
- Pablo A González
- Susan M Bueno
- Alexis M Kalergis
- Fernando Valiente-Echeverria
NIH NIAID Contract (75N93021C00016)
NIH NIAID Contract (75N9301900065)
- Daniela Weiskopf
- Alessandro Sette
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Human subjects: This clinical trial (clinicaltrials.gov NCT04651790) is a randomized and controlled study held in Chile with eight different sites. The study protocol adhered to the current Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki, and local regulations and was approved by the Institutional Scientific Ethical Committee of Health Sciences of the Pontificia Universidad Católica de Chile, (#200708006). The execution was approved by the Chilean Public Health Institute (#24204/20).